We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Legend's (LEGN) Q3 Carvykti Preliminary Sales Top Expectations
Read MoreHide Full Article
Shares of Legend Biotech Corporation (LEGN - Free Report) rose 14.2% on Oct 18 after management announced preliminary sales figures for its multiple myeloma therapy, Carvykti (ciltacabtagene autoleucel), for third-quarter 2022. The therapy has been developed in partnership with J&J (JNJ - Free Report) .
Per an SEC filing by LEGN, Carvykti generated preliminary revenues of around $55 million in net trade sales. Carvykti, a B cell maturation antigen (BCMA) CAR-T therapy, was approved by the FDA for treating relapsed or refractory multiple myeloma in February 2022.
Carvykti has been developed as part of an exclusive worldwide license and collaboration agreement entered in 2017 with Janssen Biotech, a J&J company, to develop and market Carvykti. Per the agreement, J&J is responsible for marketing the therapy, while Legend Biotech will record collaboration revenues from J&J.
In the year so far, Legend Biotech’s shares have declined 1.5% compared with the industry’s 25.0% slump.
Image Source: Zacks Investment Research
Earlier this May, Carvykti was also granted conditional marketing authorization for relapsed or refractory multiple myeloma in the European Union.
Carvykti is also Legend Biotech’s first marketed therapy. The strong sales for a recently approved therapy like Carvykti will provide Legend Biotech with a stable stream of revenues, thereby allowing management to develop its other pipeline candidates targeting hematological malignancies and solid tumors.
Please note that the figures released by LEGN are preliminary and unaudited. Final results will be issued upon completion of its closing procedures and may vary from these preliminary estimates. The $55 million preliminary sales figure for Carvykti has been provided by J&J and is yet to be verified by Legend Biotech.
Carvykti faces stiff competition from Abecma, an FDA-approved CAR-T cell therapy for multiple myeloma developed by bluebird bio (BLUE - Free Report) in collaboration with Bristol Myers (BMY - Free Report) . Per the terms of collaboration, Bristol Myers has exclusive rights to market Abecma and in return, bluebird was eligible to receive royalties. Following bluebird’s separation of its oncology business into a new separate entity with effect from November 2021, the royalties receivable on Abecma product sales along with Bristol Myers partnership were transferred to the new entity as well.
Image: Bigstock
Legend's (LEGN) Q3 Carvykti Preliminary Sales Top Expectations
Shares of Legend Biotech Corporation (LEGN - Free Report) rose 14.2% on Oct 18 after management announced preliminary sales figures for its multiple myeloma therapy, Carvykti (ciltacabtagene autoleucel), for third-quarter 2022. The therapy has been developed in partnership with J&J (JNJ - Free Report) .
Per an SEC filing by LEGN, Carvykti generated preliminary revenues of around $55 million in net trade sales. Carvykti, a B cell maturation antigen (BCMA) CAR-T therapy, was approved by the FDA for treating relapsed or refractory multiple myeloma in February 2022.
Carvykti has been developed as part of an exclusive worldwide license and collaboration agreement entered in 2017 with Janssen Biotech, a J&J company, to develop and market Carvykti. Per the agreement, J&J is responsible for marketing the therapy, while Legend Biotech will record collaboration revenues from J&J.
In the year so far, Legend Biotech’s shares have declined 1.5% compared with the industry’s 25.0% slump.
Image Source: Zacks Investment Research
Earlier this May, Carvykti was also granted conditional marketing authorization for relapsed or refractory multiple myeloma in the European Union.
Carvykti is also Legend Biotech’s first marketed therapy. The strong sales for a recently approved therapy like Carvykti will provide Legend Biotech with a stable stream of revenues, thereby allowing management to develop its other pipeline candidates targeting hematological malignancies and solid tumors.
Please note that the figures released by LEGN are preliminary and unaudited. Final results will be issued upon completion of its closing procedures and may vary from these preliminary estimates. The $55 million preliminary sales figure for Carvykti has been provided by J&J and is yet to be verified by Legend Biotech.
Carvykti faces stiff competition from Abecma, an FDA-approved CAR-T cell therapy for multiple myeloma developed by bluebird bio (BLUE - Free Report) in collaboration with Bristol Myers (BMY - Free Report) . Per the terms of collaboration, Bristol Myers has exclusive rights to market Abecma and in return, bluebird was eligible to receive royalties. Following bluebird’s separation of its oncology business into a new separate entity with effect from November 2021, the royalties receivable on Abecma product sales along with Bristol Myers partnership were transferred to the new entity as well.
Legend Biotech Corporation Sponsored ADR Price
Legend Biotech Corporation Sponsored ADR price | Legend Biotech Corporation Sponsored ADR Quote
Zacks Rank
Legend Biotech currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.